76184 – Patients living with DMT2: New treatment options and management | The 2020 CCS Atrial Fibrillation Guidelines Updates | Role of basal insulin in 2021: Facts and myths

0,00 $

Patients living with DMT2: New Treatment Options and Management Algorithms in Primary Care Setting, The 2020 CCS Atrial Fibrillation Guidelines Updates, Role of Basal Insulin in 2021: Facts and Myths.

8 still available


Objectifs d'apprentissage


AT the end of those conferences, participant will be able to:

Patients living with DMT2: New Treatment Options and Management Algorithms in Primary Care Setting
1. Identify and manage the burden of Type 2 Diabetes in order to prevent end organ damage;
2. Cite the landscape and evolution of anti-glycemic agents in Canada and choose agents based on individualized patient profiles;
3. Develop and identify clinical strategies to safely achieve individualized the glycemic targets;
4. Elaborate strategies based on personal clinical experience in order to motivate our patients incorporate changes to dietary choices and physical activity.

The 2020 CCS Atrial Fibrillation Guidelines Updates
1. Present and apply the new 2020 CCS guidelines in the treatment of AF;
2. Evaluate the impact of the new guidelines in the clinical setting and discuss and critique controversies in the management of CHADS 1 patients under 65 years old and rate vs rhythm control;
3. Demonstrate the impact of life changes and preexistent heath conditions in AF patients;
4. Identify modifiable risk factors to prevent Atrial Fibrillation and demonstrate the impact of smartwatches on the detection of Atrial Fibrillation in the clinical setting.

Role of Basal Insulin in 2021: Facts and Myths
1. Elaborate strategies to increase confidence in initiating basal insulin in the treatment of T2D and overcome patient reluctance to start insulin therapy when indicated;
2. Differentiate the benefits and limitations of the various basal insulins available in order to effectively individualize patient therapy;
3. Demonstrate how to mange changes in sulfonurea dosing when titrating basal insulin to avoid hypoglycemia;
3. Demonstrate the importance of “time in range” with respects to micro and macro vascular complications.


Président de séance : Dr Jonathan Singerman. Conférences données par les Drs Stravoula Christopoulos, Vidal Essebag et Tina Kader.


De 18 h 20 à 18 h 25, Accueil
De 18 h 25 à 19 h 25, Conférence
De 19 h 25 À 19 h 30, Pause
De 19 h 30 à 20 h 30, Conférence
De 20 h 30 à 20 h 35, Pause
De 20 h 35 à 21 h 35, Conférence


If you need any information, please contact Mr. Steven Woo from Novo Nordisk Canada at 514 219-3578 or snwo@Novonordisk.com or Mrs. Louise Charette from Pfizer Canada at 514 229-3786 or louise.charette@pfizer.com or Mrs. Josée Guillemette from Bristol-Myers Squibb Canada at 819 661-1222 or josee.guillemette@bms.com.

Reconnaissance des activités éducatives

L’Association des médecins omnipraticiens de Montréal, sous l’agrément parapluie de la FMOQ, reconnaît 3.00 heures de crédits de catégorie 1 aux participants à cette activité. Numéro FMOQ pour récupérer votre attestation : 76184.

Formation subventionnée

Cette activité bénéficie d’une subvention à visée éducative de Novo Nordisk Canada, Pfizer Canada et Bristol-Myers Squibb Canada.

Event Details

Date: 2021-02-10

Start time: 18:20 EDT

End time: 21:35 EDT

Email: snwo@Novonordisk.com, Louise.charette@pfizer.com, Josee.guillemette@bms.com